Afatinib With CT and RT for EGFR-Mutant NSCLC
This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. "Investigational" means that the drug is still being studied and that study doctors are trying to find out more about it-such as the safest dose to use, the side effects it may cause, and if the drug is effective for treating different types of cancer. It also means that the FDA has not yet approved the drug for the patients type of cancer or for any use outside of research studies.
Chemotherapy and radiation is the standard treatment for the patients with stage III non-small cell lung cancer (NSCLC). For people with epidermal growth factor receptor (EGFR) mutations, adding a type of drug called a tyrosine kinase inhibitor (TKI) can help increase the response to treatment.
Afatinib is a tyrosine kinase inhibitor. It has been studied in a previous research study in participants with more advanced NSCLC. Results from that study indicate it may be helpful in treating NSCLC with EGFR mutations.
In this study, patients with stage III NSCLC and EGFR mutations will receive the standard treatment of radiation and chemotherapy. If possible, the patients tumor will be removed by surgery. Afatinib will be given before radiation and chemotherapy and after surgery. The aim of giving afatinib before radiation therapy is to try to shrink the tumor. This may make the radiation therapy more effective since radiation therapy tends to work better on smaller tumors.
The goal of this study is to see if adding afatinib to standard treatment helps to improve the response to treatment.
|Study Design:||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Afatinib Sequenced With Concurrent Chemotherapy and Radiation in EGFR-Mutant Non-Small Cell Lung Tumors: The ASCENT Trial|
- Response Rate [ Time Frame: 2 years ] [ Designated as safety issue: No ]Assess the response rate to induction afatinib.
- 2 Year Progression-Free Survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]Estimate the 2-year progression-free survival (PFS)
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]Describe the number of patients that have side effects of various types from the study treatment
- Unresectable Disease Converted to Operable Cases [ Time Frame: 2 years ] [ Designated as safety issue: No ]Estimate the proportion of patients with initially unresectable disease that can be converted to operable cases
- Locoregional Tumor Control Rates [ Time Frame: 2 years ] [ Designated as safety issue: No ]Estimate 2-year locoregional tumor control rates, distant metastasis rates and overall survivial rates, as well as median overall survivial (OS)
- Evaluation of EGFR Mutation Status and other genotypes [ Time Frame: 2 years ] [ Designated as safety issue: No ]Evaluate the status of various relevent genes such as EGFR, MET, and other genes that might be related to response or resistance to afatinib, and assess relationship to clinical outcomes
|Study Start Date:||April 2012|
|Estimated Primary Completion Date:||April 2014 (Final data collection date for primary outcome measure)|
induction phase-two 4 week cycles. consolidation phase-twenty six 4 week cyclesRadiation: Radiation
Daily, Monday-FridayDrug: Cisplatin
Day 1 of each cycle, IV infusion over 60 minutesDrug: Pemetrexed
Day 1 of each cycle, given as IV infusion over 10 minutes after cisplatin infusionProcedure: Surgery
Surgery to remove tumor
Study treatment will be divided into 5 stages:
Stage 1-induction, consisting of afatinib for two 4-week cycles. Afatinib is a pill that the patient takes by mouth once per day. The patient will receive a study drug diary in which to record the doses of afatinib.
Stage 2-concurrent radiation and chemotherapy with cisplatin/pemetrexed for two 3-week cycles.
Stage 3-Surgery to remove tumor for participants whose tumor can be removed by surgery. This will be done about 4-6 weeks after finishing radiation and chemotherapy. The exact timing will depend upon how quickly the patient recovers from side effects of the radiation and chemotherapy. The investigators will use a piece of the patients tumor removed by surgery for research tests to look for biomarkers such as genes and proteins that may be associated with response to afatinib, chemotherapy or radiation.
Stage 4-Chemotherapy after surgery (adjuvant chemotherapy). The patients doctor will decide if the patient will receive chemotherapy after the patients surgery but before receiving consolidation with afatinib. If the patient does receive this, it will start 6-12 weeks after surgery or finishing radiation if the patient does not have surgery. The chemotherapy will be the same as that received along with the radiation therapy.
Stage 5-Consolidation with afatinib for twenty-six 4-week cycles (2 years) for participants who responded to the 2 cycles of induction afatinib.
The investigators would like to keep track of the patients medical condition and status of the patients disease for up to 5 years after the patient stops study treatment. Keeping in touch with the patients and checking on the patients condition every year helps the investigators look at the long-term effects of the research study. The patients will be asked to have CT scans as follows:
- Every 3 months for the first year after stopping study treatment
- Every 6 months for years 2-4 after stopping study treatment
- Once per year in year 5 after stopping study treatment
|Contact: Lecia V Sequist, MD MPHemail@example.com|
|United States, Massachusetts|
|Massachusetts General Hospital||Recruiting|
|Boston, Massachusetts, United States, 02215|
|Contact: Lecia V Sequist, MD MPH 617-724-4000 firstname.lastname@example.org|
|Principal Investigator: Lecia V Sequist, MD MPH|
|Dana-Farber Cancer Institute||Recruiting|
|Boston, Massachusetts, United States, 02215|
|Contact: Geoffrey Oxnard, MD 617-632-6049 email@example.com|
|Principal Investigator: Geoffrey Oxnard, MD|
|Principal Investigator:||Lecia V Sequist, MD MPH||Massachusetts General Hospital|